Bridgeway Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Bridgeway Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,375	Closed	-$487K	–	1303
2025 Q4	$487K	Sell	14,375 -6,250	-30%	-$194K	0.01%	822
2025 Q3	$532K	Buy	20,625 +5,000	+32%	+$65.4K	0.01%	793
2025 Q2	$125K	Buy	15,625 +3,125	+25%	+$23.8K	﹤0.01%	1040
2025 Q1	$122K	Sell	12,500 -3,125	-20%	-$30.7K	﹤0.01%	1002
2024 Q4	$198K	Buy	15,625 +6,250	+67%	+$79.4K	﹤0.01%	1013
2024 Q3	$151K	Buy	+9,375	New	+$190K	﹤0.01%	1111

Bridgeway Capital Management's RAPT Position: Q1 2026 in Review

Bridgeway Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 14,375 shares — an estimated $487K sold.

Bridgeway Capital Management first reported a position in RAPT in Q3 2024 and held it in 6 quarters. The position peaked at $532K in Q3 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Bridgeway Capital Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Bridgeway Capital Management sold 14,375 RAPT Therapeutics shares in Q1 2026, an estimated $487K.
Bridgeway Capital Management first reported a position in RAPT Therapeutics in Q3 2024 and held it in 6 quarters.
Bridgeway Capital Management's RAPT Therapeutics position peaked at $532K in Q3 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.